Companies / GILD vs BIIB
GILD vs BIIB: Gilead Sciences and Biogen
Gilead Sciences (GILD) reported $29.4B in revenue against a 28.9% net margin, while Biogen (BIIB) reported $9.9B at a 13.1% net margin, most recently.
| Metric | GILD | BIIB |
|---|---|---|
| Revenue | $29.4B | $9.9B |
| Net Income | $8.5B | $1.3B |
| Gross Margin | 78.8% | 75.7% |
| Operating Margin | 34.0% | 15.7% |
| EPS (Diluted) | $6.78 | $8.79 |
| Free Cash Flow | $9.5B | $2.1B |
| Total Debt | $24.9B | $6.3B |
| P/E Ratio | 18.1× | 20.0× |
| P/B Ratio | 6.7× | n/m |
| Stock Price | $167.53 | $244.12 |
Free: last 5 years
| Fiscal year | FY2007 🔒 | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| BIIB Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B |